Inhibition of histone demethylase LSD1 suppresses CD47 expression and enhances efficacy of CD47 blockade in breast cancer. [PDF]
J Immunother CancerJiang F +5 more
europepmc +1 more source
Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma. [PDF]
Expert Opin Investig DrugsPagès-Geli C, Weiskopf K.
europepmc +1 more source
SIRPγ limits effector differentiation of human CD8 T cells in response to subthreshold TCR-signaling. [PDF]
ImmunohorizonsMorse M +5 more
europepmc +1 more source
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment. [PDF]
J Immunother CancerAndón FT +4 more
europepmc +1 more source
Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents. [PDF]
Front ImmunolLi N, Yu J, Wang R, Gong G.
europepmc +1 more source
Nature-Inspired Alternatives to PEG for Next-Generation Long-Circulating Nanocarriers. [PDF]
Int J NanomedicineJan N, Rejili M.
europepmc +1 more source
TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives. [PDF]
TheranosticsZhou L, Yuan F, Wu Y, Li X, Xiang D.
europepmc +1 more source
Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives. [PDF]
J Transl MedGu Q +9 more
europepmc +1 more source
The SIRP family: from structural diversity and signaling mechanisms to implications in immune-related disease targeted therapeutics. [PDF]
Front ImmunolJin Y +6 more
europepmc +1 more source
The EphA3 Antibody Enhances CD47 Antibody-Mediated Phagocytosis by Repolarizing M2-Like Tumor-Associated Macrophages in a Preclinical Model of Recurrent Head and Neck Cancer. [PDF]
Onco Targets TherKim SH +5 more
europepmc +1 more source